貝恩資本31.6億美元私有化秦淮數據(CD.US)
於美國上市的內地數據商秦淮數據(Chindata)(CD.US)宣布獲貝恩資本提出31.6億美元進行私有化,作價每股8.6美元,較貝恩資本6月提出私有化前溢價43%。收購以全現金進行,預定今年第四季或明年初完成交易。新方案較原來方案作價上調7.5%。
貝恩資本為秦淮數據最大單一股東,持有87%投票權及42%已發行股份。貝恩資本在2020年9月把秦淮數據提交納斯達克交易所掛牌,招商局資本早前提出以34億美元收購秦淮數據,被貝恩資本拒絕。
秦淮數據在中國、印度及東南亞設有數據中心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.